We Need to Encrypt Clinical Trial Data
In the world of clinical trials, data isn’t merely valuable; it’s vital. When the screens at Change Healthcare went dark on February 21, 2024, it wasn’t just digits and databases at stake — it was lives.
In this world, each data point represents a patient’s hope, a potential breakthrough, a step towards curing disease. Yet, as the dust settled on one of the largest healthcare data breaches in history, a sobering reality emerged: Our quest to improve lives through revolutionary drug discovery has inadvertently created a treasure trove for cybercriminals.
The great news is that the digitalization of clinical trials has opened new frontiers in treatment development. However, unlike financial data, where a breach might mean monetary loss, compromised clinical trial information can derail life-saving research and betray the trust of vulnerable patients. It’s a stark reminder that in this industry, data security isn’t just about protecting assets — it’s about preserving hope and safeguarding lives.
So what do we do? We make data breaches irrelevant. This sounds like a herculean task but it is within reach. To do so, biotech companies must adopt three key strategies below:
Define Data Purpose and Sensitivity From the Start
The foundation of good data security is knowing exactly what you’re protecting and why. Before collecting any information in a clinical trial, establish a clear “use doctrine” that defines the purpose of each data point. This isn’t theoretical — it’s a practical step to prevent unnecessary accumulation of sensitive information that could become a liability.
Once data is collected, immediately identify sensitive elements. This goes beyond HIPAA compliance — it’s about recognizing that seemingly innocuous information can be exploited when combined with other data points.
What do we mean by that? Well, in theory, let’s say we have a clinical trial for a rare genetic disorder. Even basic demographic data like zip codes could be combined with publicly available information to potentially identify participants. In a small community, knowing a participant’s age, gender and general location might be enough for bad actors to narrow down and possibly identify individuals, compromising their privacy and the integrity of the trial.
By defining data purpose and sensitivity upfront, you create a concrete roadmap for implementing targeted security measures throughout the trial lifecycle. It’s far more effective than scrambling to secure data after collection.
Implement Proactive Protection Measures
You’ve heard about the right place, and right time – the same goes for data security. The moment sensitive information enters your systems, it must be protected. Too many organizations collect data first and figure out security later, leaving critical information exposed in the interim and presenting an opportunity for cybercriminals.
Encrypt sensitive data immediately upon acquisition. Implement granular access controls that limit exposure to only those who need it for the trial. These aren’t optional add-ons — they should be hardwired into your data collection process.
Instead of finding out the hard way, choose a data-centric security approach that encrypts sensitive information at the field level. This method allows you to protect specific data elements within a database or data store, such as patient identifiers or genetic markers while leaving non-sensitive data accessible for analysis. By encrypting at this granular level, you can maintain data utility for authorized users while rendering the most critical information useless to unauthorized actors.
While it’s important, a security leader’s goal isn’t just regulatory compliance — it’s staying ahead of evolving threats. Treat all trial data as sensitive and implement robust protections from the start. Creating a security-first culture capable of adapting to new challenges as they emerge should be foundational.
Leverage AI Responsibly for Enhanced Security
The words AI and power go hand in hand but Spiderman taught us that with great power comes great responsibility. Like a hero, AI-powered tools can significantly improve our ability to identify and protect sensitive information. Machine learning algorithms can swiftly analyze vast datasets to flag potential vulnerabilities or detect unusual access patterns indicative of a breach.
While specific examples of biotech companies using AI for data security in clinical trials are not widely publicized, the potential is significant. According to a recent industry report, AI-powered tools can dramatically improve threat detection and response times in healthcare cybersecurity. However, AI itself can become a target. Models trained on sensitive clinical trial data could be compromised, leading to data leaks. As AI capabilities grow, so do the sophisticated tools available to cybercriminals. Thus, responsibility.
The key is embracing “responsible AI” practices. Use AI to enhance security, but do so strategically. For highly sensitive clinical trial data, consider using local AI models that don’t require sending information to external servers. If the data is to be sent to a public LLM, it is critical to Implement robust encryption for sensitive data fields before it is sent to the LLM.
The Path Forward
As we push the boundaries of medical science through innovative clinical trials, we must recognize that data security is not an IT issue — it’s a fundamental business imperative. These strategies provide a framework for protecting sensitive information, but they require commitment from every level of the organization to be effective.
Biotech companies that prioritize data security won’t just better protect their patients and research — they’ll gain a critical competitive advantage. In an industry where trust is paramount, demonstrating an unwavering commitment to data protection can make or break a clinical trial.
The time to act is now. Our ability to develop life-saving treatments hangs in the balance.
